Document Detail


Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions.
MedLine Citation:
PMID:  23278775     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Background. Under the Revised National Tuberculosis Control Programme of India, patients with new smear-positive pulmonary tuberculosis are treated with a thrice-weekly regimen of antitubercular drugs (2H(3)R(3)Z(3)E(3)/4H(3)R(3) [H isoniazid, R rifampicin, Z pyrazinamide and E ethambutol]) for 6 months. We conducted a retrospective analysis of the efficacy andtolerability of this regimen under clinical trial conditions in HIV-negative patients with newly diagnosed smear-positive pulmonary tuberculosis. Methods. We retrospectively analysed the data on patients assigned to the control regimen (2H (3)R(3)Z(3)E(3)/4H(3)R(3)) in two clinical trials during 2001-06 at the National Institute for Research in Tuberculosis, Chennai, India. Results. Of the 268 patients treated with this regimen, data for efficacy analysis were available for 249. At the end of treatment, of 249 patients, 238 (96%) had a favourable status. Treatment failure occurred in the remaining 11: 7 in whom the organisms were initially drug-susceptible and 4 with initial drug resistance. Of the 238 patients who had a favourable status at the end of treatment, 14 (6%) had recurrence of tuberculosis during the following 24 months. In the intention-to-treat analysis, 245 (94%) of 262 patients had a favourable status at the end of treatment. Of the 28 patients with initial drug resistance, 24 (86%) had a favourable outcome. Only 4 of these 24 patients were found to have recurrence of tuberculosis in 2 years of follow-up. Among the 221 patients initially infected with drug-susceptible organisms, drug resistance did not develop in any of the 7 patients in whom the treatment failed or the 10 who had recurrence of tuberculosis. Further, 5 of the 7 patients in whom the treatment failed continued to excrete drug-susceptible bacilli at 6 months. Adverse drug reactions were observed in 38 (14%) of the 262 patients. Only 3 (1.1%) needed a modification in the treatment. Conclusion. This thrice-weekly 6-month regimen of antitubercular drugs, when administered under full supervision, is associated with a high rate of favourable treatment outcomes in HIV-negative patients with newly diagnosed sputum smearpositive pulmonary tuberculosis. There are few adverse drug reactions in these patients.
Authors:
V V Banu Rekha; K Rajaram; A S Kripasankar; R Parthasarathy; K C Umapathy; I Sheikh; N Selvakumar; M Victor; C Niruparani; R Sridhar; M S Jawahar
Related Documents :
23521155 - Metabolic and toxicological considerations for obsessive-compulsive disorder drug therapy.
23026655 - Antipsychotic drugs and venous thromboembolism.
24097305 - A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congener...
23357735 - Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (s...
8884875 - Effect of concomitant administration of clodronate and estramustine phosphate on their ...
23111325 - Dll1/notch activation contributes to bortezomib resistance by upregulating cyp1a1 in mu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The National medical journal of India     Volume:  25     ISSN:  0970-258X     ISO Abbreviation:  Natl Med J India     Publication Date:    2012 Jul-Aug
Date Detail:
Created Date:  2013-01-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8809315     Medline TA:  Natl Med J India     Country:  India    
Other Details:
Languages:  eng     Pagination:  196-200     Citation Subset:  IM    
Copyright Information:
Copyright 2012, NMJI.
Affiliation:
National Institute for Research in Tuberculosis, Indian Council of Medical Research, No.1, Mayor Sathyamoorthy Road, Chetpet, Chennai 600031, Tamil Nadu, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian vitiligo patients: ...
Next Document:  Impact of feeding and breastfeeding practices on the nutritional status of infants in a district of ...